{"disease":{"id":"manic-episode","name":"manic episode"},"drugs":{"marketed":[{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03257865","title":"A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT03259555","title":"A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":322,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04563910","title":"Impact of Duration of Untreated Manic Episodes on Clinical Outcome","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05622552","title":"Effect of tDCS Combined With Pharmacological Treatments for Bipolar Mania","phase":"NA","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Dongbin Lyu","has_results":false},{"nct_id":"NCT04874974","title":"Feasibility of a Novel Process-based Treatment for Patients With Psychosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Max-Planck-Institute of Psychiatry","has_results":false},{"nct_id":"NCT06426134","title":"Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT05956340","title":"A Study of Spoken Language in Mania","phase":"NA","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}